QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.106.011940v1 35/4/554    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mannens, G. S. J. Articles by Meuldermans, W. Search for Related Content PubMed PubMed Citation Articles by Mannens, G. S. J. Articles by Meuldermans, W.

The Absorption, Metabolism, and Excretion of the Novel Neuromodulator RWJ-333369 (1,2-Ethanediol, [1-2-Chlorophenyl]-, 2-carbamate, [S]-) in Humans

Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium (G.S.J.M., J.H., C.G.M.J., B.V.H., T.V., I.G., M.Bo., B.V., W.M.); Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey (S.C., M.K.); Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Spring House, Pennsylvania (M.F.K.); and Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel (M.Bi.)

RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-; CAS Registry Number 194085-75-1) is a novel neuromodulator in clinical development for the treatment of epilepsy. To study the disposition of RWJ-333369, eight healthy male subjects received a single oral dose of 500 mg of ¹⁴C-RWJ-333369. Urine, feces, and plasma were collected for analysis for up to 1 week after dosing. Radioactivity was mainly excreted in urine (93.8 ± 6.6%) and much less in feces (2.5 ± 1.6%). RWJ-333369 was extensively metabolized in humans, since only low amounts of parent drug were excreted in urine (1.7% on average) and feces (trace amounts). The major biotransformation pathways were direct O-glucuronidation (44% of the dose), and hydrolysis of the carbamate ester followed by oxidation to 2-chloromandelic acid, which was subsequently metabolized in parallel to 2-chlorophenyl glycine and 2-chlorobenzoic acid (mean percentage of the dose for the three acids together was 36%). Other routes were chiral inversion followed by O-glucuronidation (11%), and aromatic hydroxylation in combination with sulfate conjugation (5%). In plasma, unchanged drug accounted for 76.5% of the total radioactivity, with the R-enantiomer and the O-glucuronide of the parent drug as the only measurable plasma metabolites. With the use of very sensitive liquid chromatography-tandem mass spectrometry techniques, only traces of aromatic (pre)mercapturic acid conjugates were detected in urine (each <0.3% of the dose), suggesting a low potential for reactive metabolite formation. In conclusion, the disposition of RWJ-333369 in humans is characterized by virtually complete absorption, extensive metabolism, and unchanged drug as the only significant circulating species.

This article has been cited by other articles:

				E. Faught, G. L. Holmes, W. E. Rosenfeld, G. Novak, W. Neto, A. Greenspan, J. Schmitt, E. Yuen, S. Reines, and M. Haas Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures Neurology, November 11, 2008; 71(20): 1586 - 1593. [Abstract] [Full Text] [PDF]

				R. N. V. S. Mamidi, G. Mannens, P. Annaert, J. Hendrickx, I. Goris, M. Bockx, C. G. M. Janssen, M. Kao, M. F. Kelley, and W. Meuldermans Metabolism and Excretion of RWJ-333369 [1,2-Ethanediol, 1-(2-Chlorophenyl)-, 2-carbamate, (S)-] in Mice, Rats, Rabbits, and Dogs Drug Metab. Dispos., April 1, 2007; 35(4): 566 - 575. [Abstract] [Full Text] [PDF]